中或超低分次放疗后前列腺癌患者肠道与泌尿功能变化:前瞻性队列研究
这项前瞻性队列研究评估了真实世界前列腺癌患者接受中等分次(MHF,20×3/3.1 Gy,n=140)或超低分次(UHF,7×6.1 Gy,n=138)放疗后6个月的健康相关生活质量变化。全队列中肠道和泌尿功能发生MCID(最小临床重要差异)恶化的比例分别为20%和17%。泌尿功能恶化的多变量预测因素包括雄激素剥夺治疗、年龄≥75岁、MHF和≥2级急性泌尿毒性;肠道功能恶化未识别出预测因素。
要点
- 全队列中肠道和泌尿功能MCID恶化比例分别为20%和17%。
- 泌尿功能恶化预测因素:ADT、年龄≥75岁、MHF、≥2级急性泌尿毒性。
- 肠道功能恶化未识别出预测因素。
核心结论
- 在接受MHF和UHF治疗的真实世界前列腺癌患者中,观察到与既往试验报告相当的治疗后HRQoL变化。
- 肠道和泌尿功能恶化与一般健康状况评分较差相关。
- 泌尿功能丧失的结果提示急性泌尿毒性的后续效应。
研究设计与样本
- 前瞻性队列研究,纳入T1-4N0M0前列腺癌患者,接受MHF(20×3/3.1 Gy,n=140)或UHF(7×6.1 Gy,n=138)。
- T3b/T4疾病或基线泌尿功能受损者未接受UHF。
- 患者在基线和治疗后6个月完成EPIC泌尿和肠道域及EQ-5D-5L(一般HRQoL)问卷。
- MCID阈值定义为8%。
- 使用回归模型评估预后因素。
主要发现
- 全队列中肠道功能MCID恶化比例为20%,泌尿功能MCID恶化比例为17%。
- 膀胱和肠道功能恶化与一般健康、日常活动、疼痛/不适和抑郁/焦虑评分下降显著相关。
- 泌尿功能恶化的多变量预测因素为雄激素剥夺治疗、年龄≥75岁、MHF和≥2级急性泌尿毒性。
- 肠道功能恶化未识别出预测因素。
临床怎么用
- 对于接受MHF或UHF的前列腺癌患者,应在基线和治疗后6个月评估EPIC泌尿和肠道域及EQ-5D-5L。
- 关注具有泌尿功能恶化预测因素(ADT、年龄≥75岁、MHF、≥2级急性泌尿毒性)的患者。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE/PURPOSE: Hypofractionation (HF) has been established as safe in prostate cancer (PCa) trial populations. We evaluated post-treatment changes in health-related quality of life (HRQoL) outcomes after moderate (MHF) or ultra-hypofractionated (UHF) radiotherapy in a real-world PCa patient population. METHODS: In this prospective cohort study, T1-4N0M0 PCa patients receiving MHF (20x3/3.1 Gy, n = 140) or UHF (7x6.1 Gy, n = 138) were assessed. UHF was not prescribed in case of T3b/T4 disease or an impaired baseline urinary function. Patients completed the EPIC urinary and bowel domains and the EQ-5D-5L (general HRQoL) at baseline and 6 months post-treatment. Thresholds for minimal clinically important differences (MCID) were defined at 8 %. Prognostic factors were assessed using regression models. RESULTS: Proportion of the total cohort with MCID deterioration for bowel and urinary function was 20 % and 17 %, respectively. Deteriorations in bladder and bowel function significantly correlated with declined scores for general health, usual activities, pain/discomfort, and depression/anxiety. Predictive factors for urinary function deterioration at multivariable analysis were androgen deprivation therapy, age ≥ 75 year, MHF, and grade ≥ 2 acute urinary toxicity. For bowel function deterioration, no factors were identified. CONCLUSION: We assessed post-treatment changes in HRQoL in a clinical PCa patient population treated with MHF and UHF, and observed changes comparable to previous trial reports. Deteriorations in bowel and urinary function correlated with worse general health scores. Results for urinary function loss suggested a consequential effect of acute urinary toxicity.
引用
- Heemsbergen WD, Sinzabakira F, de Vries KC, et al. Post-treatment changes in bowel and urinary function in prostate cancer patients treated with moderate or ultra-hypofractionation: A prospective cohort study. Clin Transl Radiat Oncol. 2025. PMID: 40248007. doi:10.1016/j.ctro.2025.100955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。